{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T04:30:09Z","timestamp":1717216209256},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T00:00:00Z","timestamp":1234137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T00:00:00Z","timestamp":1234137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1038\/bmt.2008.441","type":"journal-article","created":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T17:33:36Z","timestamp":1234200816000},"page":"169-174","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients"],"prefix":"10.1038","volume":"44","author":[{"given":"M J","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Trotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D J","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K S","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J E","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Verneris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,9]]},"reference":[{"key":"BFbmt2008441_CR1","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/315758a0","volume":"315","author":"N Heisterkamp","year":"1985","unstructured":"Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G . Structural organization of the bcr gene and its role in the Ph+ translocation. Nature 1985; 315: 758\u2013761.","journal-title":"Nature"},{"key":"BFbmt2008441_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079\u20131082.","journal-title":"Science"},{"key":"BFbmt2008441_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFbmt2008441_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, Jones D, Giles F, Garcia-Manero G et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 835\u20131840.","journal-title":"Blood"},{"key":"BFbmt2008441_CR5","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478\u20131484.","journal-title":"Blood"},{"key":"BFbmt2008441_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908\u2013916.","journal-title":"Nat Med"},{"key":"BFbmt2008441_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/sj.leu.2402565","volume":"16","author":"T Fischer","year":"2002","unstructured":"Fischer T, Reifenrath C, Hess GR, Corsetti MT, Kreil S, Beck J et al. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr\/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 2002; 16: 1220\u20131228.","journal-title":"Leukemia"},{"key":"BFbmt2008441_CR8","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530\u20133539.","journal-title":"Blood"},{"key":"BFbmt2008441_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1046\/j.1365-2141.2003.04288.x","volume":"121","author":"SK Sohn","year":"2003","unstructured":"Sohn SK, Kim JG, Kim DH, Lee KB . Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan\/cyclophosphamide conditioning after imatinib mesylate administration. Br J Haematol 2003; 121: 469\u2013472.","journal-title":"Br J Haematol"},{"key":"BFbmt2008441_CR10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R . US Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005; 11: 12\u201329.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2008441_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0107-13b","volume":"13","author":"C Gambacorti-Passerini","year":"2007","unstructured":"Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E . In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019. Nat Med 2007; 13: 13\u201314; author reply 15\u201316.","journal-title":"Nat Med"},{"key":"BFbmt2008441_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0107-13a","volume":"13","author":"A Hatfield","year":"2007","unstructured":"Hatfield A, Owen S, Pilot PR . In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019. Nat Med 2007; 13: 13; author reply 15\u201316.","journal-title":"Nat Med"},{"key":"BFbmt2008441_CR13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","volume":"110","author":"E Atallah","year":"2007","unstructured":"Atallah E, Durand JB, Kantarjian H, Cortes J . Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233\u20131237.","journal-title":"Blood"},{"key":"BFbmt2008441_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/hrt.69.6.496","volume":"69","author":"F Orzan","year":"1993","unstructured":"Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC . Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 1993; 69: 496\u2013500.","journal-title":"Br Heart J"},{"key":"BFbmt2008441_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/00001721-199609000-00006","volume":"7","author":"E Morishita","year":"1996","unstructured":"Morishita E, Nakao S, Asakura H, Jokaji H, Saito M, Uotani C et al. Hypercoagulability and high lipoprotein(a) levels in patients with aplastic anemia receiving cyclosporine. Blood Coagul Fibrinolysis 1996; 7: 609\u2013614.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"BFbmt2008441_CR16","first-page":"452","volume":"91","author":"M Deininger","year":"2006","unstructured":"Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452\u2013459.","journal-title":"Haematologica"},{"key":"BFbmt2008441_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","volume":"137","author":"SA Giralt","year":"2007","unstructured":"Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461\u2013467.","journal-title":"Br J Haematol"},{"key":"BFbmt2008441_CR18","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","volume":"109","author":"VG Oehler","year":"2007","unstructured":"Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782\u20131789.","journal-title":"Blood"},{"key":"BFbmt2008441_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.bmt.1705087","volume":"36","author":"JM Zaucha","year":"2005","unstructured":"Zaucha JM, Prejzner W, Giebel S, Gooley TA, Szatkowski D, Kalwak K et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 417\u2013424.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2008441_CR20","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473\u20132479.","journal-title":"Blood"},{"key":"BFbmt2008441_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","volume":"23","author":"S Appel","year":"2005","unstructured":"Appel S, Balabanov S, Brummendorf TH, Brossart P . Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005; 23: 1082\u20131088.","journal-title":"Stem Cells"},{"key":"BFbmt2008441_CR22","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","volume":"109","author":"PA Carpenter","year":"2007","unstructured":"Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791\u20132793.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2008441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008441","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2008441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T11:04:03Z","timestamp":1710068643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2008441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["BFbmt2008441"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2008.441","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,9]]},"assertion":[{"value":"3 September 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}